GeoVax Labs Q4 2025 Earnings Report

GeoVax Labs EPS Results

• Actual EPS: -$2.62
• Consensus EPS: -$3.84
• Beat/Miss: Beat by +$1.22
• One Year Ago EPS: N/A

GeoVax Labs Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

GeoVax Labs Announcement Details

• Quarter: Q4 2025
• Date: 5/14/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

GeoVax Labs (NASDAQ:GOVX), Inc. is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs. This dual approach is designed to stimulate both cellular and humoral immunity, a feature that has supported advancement of the company’s HIV vaccine candidate through Phase 2 clinical trials. GeoVax is also applying this platform to develop next-generation vaccines for hemorrhagic fever viruses and novel coronaviruses, targeting populations in regions prone to outbreaks as well as frontline health workers.

Founded in 2001 and headquartered in Atlanta, Georgia, GeoVax operates in collaboration with academic institutions, government agencies and non-profit organizations. The company has received funding and technical support from the National Institutes of Health (NIH), the U.S. Department of Defense and other global health partners. These collaborations have advanced preclinical programs and facilitated clinical trial design, positioning GeoVax to rapidly respond to emerging infectious disease challenges.

Leadership at GeoVax is headed by President and Chief Executive Officer James W. Bunn, who brings more than two decades of experience in biotechnology operations and clinical development. Under his direction, the management team continues to refine the company’s vaccine platform and expand its pipeline. GeoVax’s board of directors and scientific advisory board comprise experts in virology, immunology and vaccine development, guiding strategic decisions as the company advances toward late-stage clinical studies and potential licensing partnerships.